{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:24:28Z","timestamp":1786940668684,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06256-4","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:09:05Z","timestamp":1784362145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7324-7463","authenticated-orcid":false,"given":"Wiktoria","family":"Niebudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1005-8646","authenticated-orcid":false,"given":"Micha\u0142","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-0539","authenticated-orcid":false,"given":"Martyna","family":"Dziewit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3028-1061","authenticated-orcid":false,"given":"Marzena","family":"Olesi\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2211-0302","authenticated-orcid":false,"given":"Maria","family":"Ma\u015bli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"6256_CR1","first-page":"70","volume":"88","author":"LE Shulman","year":"1975","unstructured":"Shulman LE (1975) Diffuse fasciitis with eosinophilia: a new syndrome? Trans Assoc Am Physicians 88:70\u201386","journal-title":"Trans Assoc Am Physicians"},{"key":"6256_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111275","author":"R Foti","year":"2021","unstructured":"Foti R, De Pasquale R, Dal Bosco Y, Visalli E, Amato G, Gangemi P, Foti R, Ramondetta A (2021) Clinical and histopathological features of scleroderma-like disorders: an update. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina57111275","journal-title":"Medicina (Kaunas)"},{"key":"6256_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.alit.2019.03.001","volume":"68","author":"H Ihn","year":"2019","unstructured":"Ihn H (2019) Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int 68:437\u2013439. https:\/\/doi.org\/10.1016\/j.alit.2019.03.001","journal-title":"Allergol Int"},{"key":"6256_CR4","doi-asserted-by":"publisher","first-page":"1351675","DOI":"10.3389\/fimmu.2024.1351675","volume":"15","author":"K Romanowska-Pr\u00f3chnicka","year":"2024","unstructured":"Romanowska-Pr\u00f3chnicka K, Dziewit M, Lesiak A, Reich A, Olesi\u0144ska M (2024) Scleroderma and scleroderma-like syndromes. Front Immunol 15:1351675. https:\/\/doi.org\/10.3389\/fimmu.2024.1351675","journal-title":"Front Immunol"},{"key":"6256_CR5","first-page":"1811","volume":"30","author":"C Toquet","year":"2003","unstructured":"Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S, Laboisse C, Mussini JM (2003) In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 30:1811\u20131815","journal-title":"J Rheumatol"},{"key":"6256_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1346-8138.14160","volume":"45","author":"M Jinnin","year":"2018","unstructured":"Jinnin M, Yamamoto T, Asano Y, Ishikawa O, Sato S, Takehara K, Hasegawa M, Fujimoto M, Ihn H (2018) Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol 45:881\u2013890. https:\/\/doi.org\/10.1111\/1346-8138.14160","journal-title":"J Dermatol"},{"key":"6256_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamadermatol.2015.3648","volume":"152","author":"NA Wright","year":"2016","unstructured":"Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA (2016) Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol 152:97\u201399. https:\/\/doi.org\/10.1001\/jamadermatol.2015.3648","journal-title":"JAMA Dermatol"},{"key":"6256_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","volume":"51","author":"D Lebeaux","year":"2012","unstructured":"Lebeaux D, Franc\u00e8s C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfoss\u00e9 M, Bourgeois P et al (2012) Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 51:557\u2013561. https:\/\/doi.org\/10.1093\/rheumatology\/ker366","journal-title":"Rheumatology (Oxford)"},{"key":"6256_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77615","volume":"17","author":"E Macedo Br\u00e1s","year":"2025","unstructured":"Macedo Br\u00e1s E, Sousa AP, Ferreira da Silva N, Salvador F (2025) Eosinophilic fasciitis: a case series. Cureus 17:e77615. https:\/\/doi.org\/10.7759\/cureus.77615","journal-title":"Cureus"},{"key":"6256_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.31138\/mjr.34.1.78","volume":"34","author":"S El Iskandarani","year":"2023","unstructured":"El Iskandarani S, Khasho M, Merashli M (2023) Tocilizumab in the treatment of eosinophilic fasciitis: a case study and review of literature. Mediterr J Rheumatol 34:78\u201385. https:\/\/doi.org\/10.31138\/mjr.34.1.78","journal-title":"Mediterr J Rheumatol"},{"key":"6256_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00296-021-04887-3","volume":"41","author":"N Kougkas","year":"2021","unstructured":"Kougkas N, Bertsias G, Papalopoulos I, Repa A, Sidiropoulos P, Avgoustidis N (2021) Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review. Rheumatol Int 41:1833\u20131837. https:\/\/doi.org\/10.1007\/s00296-021-04887-3","journal-title":"Rheumatol Int"},{"key":"6256_CR12","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.36849\/jdd.8017","volume":"23","author":"B Obiakor","year":"2024","unstructured":"Obiakor B, Fan W, Jacobson R, Gandelman J, Haemel A (2024) Functional and cutaneous treatment outcomes with intravenous immunoglobulin for eosinophilic fasciitis: a retrospective study. J Drugs Dermatol 23:e107\u2013e109. https:\/\/doi.org\/10.36849\/jdd.8017","journal-title":"J Drugs Dermatol"},{"key":"6256_CR13","unstructured":"XXX"},{"key":"6256_CR14","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.3346\/jkms.2024.39.e225","volume":"39","author":"IC Benlidayi","year":"2024","unstructured":"Benlidayi IC, Gupta L (2024) CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors. J Korean Med Sci 39:e225. https:\/\/doi.org\/10.3346\/jkms.2024.39.e225","journal-title":"J Korean Med Sci"},{"key":"6256_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-024-00222-6","author":"A Selva-O'Callaghan","year":"2025","unstructured":"Selva-O\u2019Callaghan A, Trallero-Aragu\u00e1s E, Gil-Vila A, Guillen-Del Castillo A, Matas-Garc\u00eda A, Milisenda JC, Simeon-Aznar CP, Pinal-Fernandez I (2025) Treatment and monitoring of eosinophilic fasciitis. Curr Treatm Opt Rheumatol. https:\/\/doi.org\/10.1007\/s40674-024-00222-6","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"6256_CR16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jbspin.2015.02.008","volume":"82","author":"F Espinoza","year":"2015","unstructured":"Espinoza F, Jorgensen C, Pers YM (2015) Efficacy of tocilizumab in the treatment of eosinophilic fasciitis: report of one case. Joint Bone Spine 82:460\u2013461. https:\/\/doi.org\/10.1016\/j.jbspin.2015.02.008","journal-title":"Joint Bone Spine"},{"key":"6256_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA (2018) Treatment of generalized deep morphea and eosinophilic fasciitis with the janus kinase inhibitor tofacitinib. JAAD Case Rep 4:443\u2013445. https:\/\/doi.org\/10.1016\/j.jdcr.2017.12.003","journal-title":"JAAD Case Rep"},{"key":"6256_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s10067-020-04952-5","volume":"39","author":"F V\u00edlchez-Oya","year":"2020","unstructured":"V\u00edlchez-Oya F, S\u00e1nchez-Schmidt JM, Agust\u00ed A, Pros A (2020) The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review. Clin Rheumatol 39:1693\u20131698. https:\/\/doi.org\/10.1007\/s10067-020-04952-5","journal-title":"Clin Rheumatol"},{"key":"6256_CR19","doi-asserted-by":"publisher","first-page":"001485","DOI":"10.12890\/2020_001485","volume":"7","author":"G Pinheiro","year":"2020","unstructured":"Pinheiro G, Costa AR, Campar A, Mendon\u00e7a T (2020) Effectiveness of tocilizumab in the treatment of fasciitis with eosinophilia: two case reports. Eur J Case Rep Intern Med 7:001485. https:\/\/doi.org\/10.12890\/2020_001485","journal-title":"Eur J Case Rep Intern Med"},{"key":"6256_CR20","doi-asserted-by":"publisher","first-page":"e25359","DOI":"10.1097\/md.0000000000025359","volume":"100","author":"D Erez","year":"2021","unstructured":"Erez D, Shoenfeld Y, Natour A, Dovrish Z, Tayer-Shifman OE, Levy Y (2021) Clinical experience with biologic treatment in resistant eosinophilic fasciitis: case reports and review of the literature. Med (Baltim) 100:e25359. https:\/\/doi.org\/10.1097\/md.0000000000025359","journal-title":"Med (Baltim)"},{"key":"6256_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10067-025-07850-w","volume":"45","author":"SB Ali","year":"2026","unstructured":"Ali SB, Khoo T, Marshman G, Newland K, Goldblatt F (2026) The utility of rituximab in patients with eosinophilic fasciitis: case series from an Australian tertiary multidisciplinary clinic. Clin Rheumatol 45:559\u2013572. https:\/\/doi.org\/10.1007\/s10067-025-07850-w","journal-title":"Clin Rheumatol"},{"key":"6256_CR22","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.55563\/clinexprheumatol\/j7gexb","volume":"41","author":"SN Sanchez-Melendez","year":"2023","unstructured":"Sanchez-Melendez SN, Shaw KS, Pan CX, Taylor DL, Shahriari N, Mazori DR, Vleugels RA (2023) Mepolizumab for refractory eosinophilic fasciitis: a retrospective analysis from two tertiary care centres. Clin Exp Rheumatol 41:1721\u20131722. https:\/\/doi.org\/10.55563\/clinexprheumatol\/j7gexb","journal-title":"Clin Exp Rheumatol"},{"key":"6256_CR23","doi-asserted-by":"publisher","first-page":"763","DOI":"10.55563\/clinexprheumatol\/oxy3ip","volume":"41","author":"C Rizzo","year":"2023","unstructured":"Rizzo C, La Barbera L, Camarda F, Destro Castaniti GM, Orlando E, Guggino G (2023) Successful treatment of eosinophilic fasciitis with the anti-IL5 receptor monoclonal antibody benralizumab. Clin Exp Rheumatol 41:763\u2013764. https:\/\/doi.org\/10.55563\/clinexprheumatol\/oxy3ip","journal-title":"Clin Exp Rheumatol"},{"key":"6256_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.31138\/mjr.301223.itr","volume":"34","author":"A Angelopoulos","year":"2023","unstructured":"Angelopoulos A, Kouverianos I, Daoussis D (2023) Is there a role for anti-IL-5 therapies in eosinophilic fasciitis? Mediterr J Rheumatol 34:414\u2013417. https:\/\/doi.org\/10.31138\/mjr.301223.itr","journal-title":"Mediterr J Rheumatol"},{"key":"6256_CR25","first-page":"567","volume":"38","author":"XY Cao","year":"2020","unstructured":"Cao XY, Zhao JL, Hou Y, Wang FD, Lu ZH (2020) Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis. Clin Exp Rheumatol 38:567\u2013568","journal-title":"Clin Exp Rheumatol"},{"key":"6256_CR26","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3899\/jrheum.200998","volume":"48","author":"R Sehgal","year":"2021","unstructured":"Sehgal R, Ernste FC, Eckloff S (2021) Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis. J Rheumatol 48:948\u2013949. https:\/\/doi.org\/10.3899\/jrheum.200998","journal-title":"J Rheumatol"},{"key":"6256_CR27","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/rheumatology\/keq062","volume":"49","author":"D Khanna","year":"2010","unstructured":"Khanna D, Agrawal H, Clements PJ (2010) Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. Rheumatology (Oxford) 49:1184\u20131188. https:\/\/doi.org\/10.1093\/rheumatology\/keq062","journal-title":"Rheumatology (Oxford)"},{"key":"6256_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.rceng.2021.12.003","volume":"222","author":"AM Brandy-Garc\u00eda","year":"2022","unstructured":"Brandy-Garc\u00eda AM, Fern\u00e1ndez S, Pamp\u00edn-S\u00e1nchez R (2022) Tocilizumab in the treatment of eosinophilic fasciitis: case report and literature review. Rev Clin Esp (Barc) 222:440\u2013442. https:\/\/doi.org\/10.1016\/j.rceng.2021.12.003","journal-title":"Rev Clin Esp (Barc)"},{"key":"6256_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/reum.2019.84813","volume":"57","author":"J Urzal","year":"2019","unstructured":"Urzal J, Cimbron M, Mendon\u00e7a T, Farinha F (2019) Eosinophilic fasciitis (Shulman\u2019s disease): review and comparative evaluation of seven patients. Reumatologia 57:85\u201390. https:\/\/doi.org\/10.5114\/reum.2019.84813","journal-title":"Reumatologia"},{"issue":"1","key":"6256_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12969-024-00960-w","volume":"22","author":"LA Stubbs","year":"2024","unstructured":"Stubbs LA, Ogunbona O, Beil E, Szafron V, Adesina A, Anvari S, Lai J, Ramirez A, Ditzler MG, DeGuzman M (2024) Juvenile eosinophilic fasciitis: a single center case series. Pediatr Rheumatol Online J 22:29. https:\/\/doi.org\/10.1186\/s12969-024-00960-w","journal-title":"Pediatr Rheumatol Online J"},{"key":"6256_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.71766","volume":"14","author":"M Sahebari","year":"2026","unstructured":"Sahebari M, Karimoddini M, Tayyebi Meibodi N, Ataei Azimi S, Tafreshian S (2026) Rituximab and intravenous immunoglobulin (IVIG) for refractory eosinophilic fasciitis: a case report. Clin Case Rep 14:e71766. https:\/\/doi.org\/10.1002\/ccr3.71766","journal-title":"Clin Case Rep"},{"key":"6256_CR32","doi-asserted-by":"publisher","DOI":"10.5070\/d327854694","author":"C Kromer","year":"2021","unstructured":"Kromer C, Matzke SS, Bleckmann A, Overbeck T, Lippert U, Sch\u00f6n MP, M\u00f6ssner R (2021) Response of eosinophilic fasciitis associated with Waldenstr\u00f6m macroglobulinemia to rituximab. Dermatol Online J. https:\/\/doi.org\/10.5070\/d327854694","journal-title":"Dermatol Online J"},{"key":"6256_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/ijd.13940","volume":"57","author":"AF Nahhas","year":"2018","unstructured":"Nahhas AF, Alam M, Lim HW (2018) Rituximab as a therapeutic consideration for refractory eosinophilic fasciitis. Int J Dermatol 57:614\u2013615. https:\/\/doi.org\/10.1111\/ijd.13940","journal-title":"Int J Dermatol"},{"key":"6256_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MD.0b013e3182899e78","volume":"92","author":"A de Masson","year":"2013","unstructured":"de Masson A, Bouaziz JD, de Latour RP, Benhamou Y, Molu\u00e7on-Chabrot C, Bay JO, Laquerri\u00e8re A, Picquenot JM, Michonneau D, Leguy-Seguin V et al (2013) Severe aplastic anemia associated with eosinophilic fasciitis: report of 4 cases and review of the literature. Medicine (Baltimore) 92:69\u201381. https:\/\/doi.org\/10.1097\/MD.0b013e3182899e78","journal-title":"Medicine (Baltimore)"},{"key":"6256_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jdcr.2017.09.006","volume":"4","author":"WH Chan","year":"2018","unstructured":"Chan WH, Lewis DJ, Kim EJ, Aung PP, Duvic M (2018) Generalized morphea\/eosinophilic fasciitis overlap after epoxy exposure. JAAD Case Rep 4:175\u2013178. https:\/\/doi.org\/10.1016\/j.jdcr.2017.09.006","journal-title":"JAAD Case Rep"},{"key":"6256_CR36","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s00296-021-04787-6","volume":"41","author":"N Jim\u00e9nez-Garc\u00eda","year":"2021","unstructured":"Jim\u00e9nez-Garc\u00eda N, Aguilar-Garc\u00eda J, Fern\u00e1ndez-Canedo I, Bl\u00e1zquez-S\u00e1nchez N, F\u00fanez-Li\u00e9bana R, Romero-G\u00f3mez C (2021) Eosinophilic fasciitis in a pregnant woman with corticosteroid dependence and good response to infliximab. Rheumatol Int 41:1531\u20131539. https:\/\/doi.org\/10.1007\/s00296-021-04787-6","journal-title":"Rheumatol Int"},{"key":"6256_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/23971983211004399","volume":"6","author":"P \u015amigielska","year":"2021","unstructured":"\u015amigielska P, Czarny J, Kowalski J, Wilkowska A, Nowicki RJ (2021) Refractory eosinophilic fasciitis successfully treated with infliximab: a case report. J Scleroderma Relat Disord 6:211\u2013213. https:\/\/doi.org\/10.1177\/23971983211004399","journal-title":"J Scleroderma Relat Disord"},{"key":"6256_CR38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.anai.2011.01.021","volume":"106","author":"N Poliak","year":"2011","unstructured":"Poliak N, Orange JS, Pawel BR, Weiss PF (2011) Eosinophilic fasciitis mimicking angioedema and treatment response to infliximab in a pediatric patient. Ann Allergy Asthma Immunol 106:444\u2013445. https:\/\/doi.org\/10.1016\/j.anai.2011.01.021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"6256_CR39","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/rheumatology\/ken142","volume":"47","author":"N Tzaribachev","year":"2008","unstructured":"Tzaribachev N, Holzer U, Schedel J, Maier V, Klein R, Kuemmerle-Deschner J (2008) Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis. Rheumatology (Oxford) 47:930\u2013932. https:\/\/doi.org\/10.1093\/rheumatology\/ken142","journal-title":"Rheumatology (Oxford)"},{"key":"6256_CR40","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/1346-8138.16604","volume":"49","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Chmelar C, Philippou S, Szeimies RM, Chatzipantazi M (2022) Gleich syndrome and eosinophilic fasciitis overlap successfully treated with mepolizumab. J Dermatol 49:1348\u20131350. https:\/\/doi.org\/10.1111\/1346-8138.16604","journal-title":"J Dermatol"},{"key":"6256_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jdcr.2023.08.003","volume":"40","author":"MJ Woodbury","year":"2023","unstructured":"Woodbury MJ, Gaffney RG, Merola JF (2023) A case of paradoxical eosinophilic fasciitis in a patient on benralizumab. JAAD Case Rep 40:45\u201346. https:\/\/doi.org\/10.1016\/j.jdcr.2023.08.003","journal-title":"JAAD Case Rep"},{"key":"6256_CR42","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/ced.15379","volume":"47","author":"R Xia","year":"2022","unstructured":"Xia R, Liu J, Su T, Xia J, Yin Z (2022) Dupilumab for treatment of eosinophilic fasciitis. Clin Exp Dermatol 47:2298\u20132300. https:\/\/doi.org\/10.1111\/ced.15379","journal-title":"Clin Exp Dermatol"},{"key":"6256_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.anai.2024.05.015","volume":"133","author":"C Wang","year":"2024","unstructured":"Wang C, Flood E, Klion AD, Constantine G, Khoury P (2024) The use of dupilumab in treatment-refractory eosinophilic fasciitis. Ann Allergy Asthma Immunol 133:213\u2013215. https:\/\/doi.org\/10.1016\/j.anai.2024.05.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"6256_CR44","doi-asserted-by":"publisher","DOI":"10.12659\/ajcr.948323","volume":"26","author":"I Oke","year":"2025","unstructured":"Oke I, Lenert A, Swick BL, Lenert P (2025) Eosinophilic fasciitis in a 78-year-old man following pembrolizumab treatment for bladder cancer. Am J Case Rep 26:e948323. https:\/\/doi.org\/10.12659\/ajcr.948323","journal-title":"Am J Case Rep"},{"key":"6256_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamadermatol.2016.0048","volume":"152","author":"VS Oza","year":"2016","unstructured":"Oza VS, Walsh R, North J, Berger TG, Murase JE (2016) Treatment of eosinophilic fasciitis with sirolimus. JAMA Dermatol 152:488\u2013490. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0048","journal-title":"JAMA Dermatol"},{"key":"6256_CR46","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.jtho.2019.09.011","volume":"15","author":"E Le Tallec","year":"2020","unstructured":"Le Tallec E, Lescoat A, Ballerie A, Cador B, Lena H, Ricordel C, Damien S, Lebbe C, Jego P, Belhomme N (2020) Eosinophilic fasciitis triggered by nivolumab: a remarkable efficacy of the mTOR inhibitor sirolimus. J Thorac Oncol 15:e29\u2013e30. https:\/\/doi.org\/10.1016\/j.jtho.2019.09.011","journal-title":"J Thorac Oncol"},{"key":"6256_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jdcr.2020.07.039","volume":"6","author":"M Mortezavi","year":"2020","unstructured":"Mortezavi M, Barrett M, Edrissian M (2020) Successful treatment of refractory eosinophilic fasciitis with reslizumab. JAAD Case Rep 6:951\u2013953. https:\/\/doi.org\/10.1016\/j.jdcr.2020.07.039","journal-title":"JAAD Case Rep"},{"key":"6256_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3899\/jrheum.211126","volume":"49","author":"G Wang","year":"2022","unstructured":"Wang G, Zhuo N, Li J (2022) Baricitinib for refractory eosinophilic fasciitis: myth or reality? J Rheumatol 49:546\u2013547. https:\/\/doi.org\/10.3899\/jrheum.211126","journal-title":"J Rheumatol"},{"key":"6256_CR49","doi-asserted-by":"publisher","first-page":"T1003","DOI":"10.1016\/j.ad.2024.09.002","volume":"115","author":"B V\u00e1zquez Losada","year":"2024","unstructured":"V\u00e1zquez Losada B, Garc\u00eda Mart\u00ednez M, Villafani Echazu WJ, Hidalgo Garc\u00eda Y (2024) [Translated article] Refractory eosinophilic fasciitis: good response to ocrelizumab in a patient with multiple sclerosis under treatment with natalizumab. Actas Dermosifiliogr 115:T1003-t1005. https:\/\/doi.org\/10.1016\/j.ad.2024.09.002","journal-title":"Actas Dermosifiliogr"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06256-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:37:36Z","timestamp":1786937856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06256-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["6256"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06256-4","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the clinical details and accompanying images was obtained from the patient\u2019s parents, in accordance with the Declaration of Helsinki and COPE best practice guidelines.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"215"}}